Cytori Therapeutics (CYTX) 2.01 $CYTX
Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease
BusinessWire - Tue Jun 28, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the results from the ATHENA Trials have been published and are now available online in Catheterization and Cardiovascular Interventions, a leading international journal covering the broad field of cardiovascular diseases and the official journal of The Society for Cardiovascular Angiography and Interventions that has over 4,300 interventional and invasive cardiologist members in over 70 countries.
CYTX: 2.01 (unch)
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan
BusinessWire - Mon Jun 27, 4:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the use of Cytori Cell Therapy(TM) was approved for clinical use on June 24th, 2016 to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese 'Act on the Safety of Regenerative Medicine' that was enacted on November 25, 2014.
CYTX: 2.01 (unch)
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million
BusinessWire - Wed Jun 15, 4:00PM CDT
Cytori Therapeutics, Inc. ("Cytori" or the "Company"
(NASDAQ: CYTX) announced today the closing of its rights offering ("Rights Offering" to subscribe for units at a subscription price of $2.55 per unit.
CYTX: 2.01 (unch)
Cytori Cell Therapy(TM) Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model
BusinessWire - Fri Jun 10, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large animal model of urethral injury.
CYTX: 2.01 (unch)
Presentation of Twelve Month Pilot Trial Data of Cytori(R) Cell Therapy(TM) for ACL Reconstruction
BusinessWire - Wed Jun 08, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today Dr. Ramon Cugat MD, Ph.D. will present 12-month follow-up results from a 20-patient, single arm, open label pilot study on the use of Cytori Cell Therapy in anterior cruciate ligament (ACL) reconstruction. The presentation is titled 'Biological Augmentation of ACL Reconstruction' and will be made to The Orthobiologic Institute (TOBI) 7th Annual PRP and Regenerative Medicine Symposium in Las Vegas on June 10, 2016.
CYTX: 2.01 (unch)
Cytori Announces Enrollment Completion in U.S. Phase III Scleroderma Trial
BusinessWire - Tue Jun 07, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced completion of enrollment for its U.S. FDA approved Phase III STAR trial. A total of 88 patients were enrolled ahead of schedule, and all procedures were completed successfully without complications.
CYTX: 2.01 (unch)
Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing
BusinessWire - Mon Jun 06, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and adjusted the subscription price for its previously announced rights offering until 5:00 PM Eastern Time on Friday, June 10, 2016. Rights holders will need to exercise their subscription rights prior to that date and time. The adjusted unit pricing is now $2.55 per unit. Furthermore, Cytori invites stockholders to call in for a corporate presentation on Monday, June 6, 2016, at 2:00 PM Eastern Time.
CYTX: 2.01 (unch)
Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
BusinessWire - Tue May 31, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants to purchase shares of common stock to existing stockholders. The rights offering will remain open until 5:00 PM Eastern Time on Thursday, June 9, 2016, unless extended. Rights holders will need to exercise their subscription rights prior to that date and time.
CYTX: 2.01 (unch)
Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial
BusinessWire - Wed May 25, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
CYTX: 2.01 (unch)
Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering
BusinessWire - Tue May 17, 6:15AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering. Stockholders are advised to ensure they own Cytori's stock as of 4:00 PM ET on Tuesday, May 17, 2016 to be considered a stockholder of record on Friday, May 20, 2016. Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below.
CYTX: 2.01 (unch)
European Scleroderma Trial Investigating Cytori Cell Therapy to Be Presented in Japan
BusinessWire - Tue May 17, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use of Cytori Cell Therapy in the treatment of scleroderma-related hand dysfunction will be delivered at the 104th Annual Meeting of the Japan Society of Aesthetic Surgery in Tokyo, Japan.
CYTX: 2.01 (unch)
Cytori Reports First Quarter 2016 Business and Financial Results
BusinessWire - Tue May 10, 3:25PM CDT
Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company" today announced its first quarter financial results and provided updates on its corporate activity and clinical development.
CYTX: 2.01 (unch)
Cytori Granted Broad European Orphan Drug Designation
BusinessWire - Tue May 10, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy(R) formulations when used for the treatment of hand dysfunction and Raynaud's Phenomenon in patients with scleroderma.
CYTX: 2.01 (unch)
Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy
BusinessWire - Fri May 06, 7:39AM CDT
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today the presentation of six and twelve month data from the ATHENA Trials at the annual meeting of The Society for Cardiovascular Angiography and Interventions. The ATHENA trials are two prospective, randomized (2:1, active : placebo), double-blind, controlled, parallel group trials (ATHENA and ATHENA II) each assessing Cytori Cell Therapy(R) [ATHENA: 20 million cells, 28 patients; ATHENA II: 40 million cells, 3 patients]. The objective of the ATHENA program was assessment of safety and feasibility of Cytori Cell Therapy using the Celution(R) System automated on-site manufacturing of the cellular therapeutic and intramyocardial delivery for treatment of chronic ischemic heart disease with left heart failure.
CYTX: 2.01 (unch)
Cytori Reports Preliminary Preclinical Data Supporting Use of Cytori Cell Therapy(TM) for Both the Prevention and Treatment of Hypertrophic Scars
BusinessWire - Thu May 05, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today presented preclinical data at the Annual Meeting of the American Burn Association (ABA) in Las Vegas showing the potential of Cytori's DCCT-10 cell therapy for hypertrophic scarring (HTS), a common consequence of burn injury.
CYTX: 2.01 (unch)
Cytori to Webcast First Quarter Financial Results on May 10
BusinessWire - Fri Apr 29, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Tuesday, May 10, 2016 at 5:30 PM Eastern Time.
CYTX: 2.01 (unch)
Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.01 (unch), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial
BusinessWire - Wed Apr 27, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 60th patient (75% of target enrollment). In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 40 patients and recommended that the study continue as planned. The 60 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully without complications.
CYTX: 2.01 (unch)
Cytori Therapeutics (CYTX) Shows Strength: Stock Up 13.2%
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:15AM CDT
Cytori Therapeutics, Inc. (CYTX) shares rose above 13% in the last trading session.
CYTX: 2.01 (unch), ANIK: 52.79 (-0.51)
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016
ACCESSWIRE - Mon Apr 18, 10:17AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SKLN, STEM, CYTX, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
SKLN: 0.14 (unch), CYTX: 2.01 (unch), STEM: 0.39 (-0.01)
Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease
BusinessWire - Tue Jun 28, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the results from the ATHENA Trials have been published and are now available online in Catheterization and Cardiovascular Interventions, a leading international journal covering the broad field of cardiovascular diseases and the official journal of The Society for Cardiovascular Angiography and Interventions that has over 4,300 interventional and invasive cardiologist members in over 70 countries.
CYTX: 2.01 (unch)
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan
BusinessWire - Mon Jun 27, 4:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the use of Cytori Cell Therapy(TM) was approved for clinical use on June 24th, 2016 to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese 'Act on the Safety of Regenerative Medicine' that was enacted on November 25, 2014.
CYTX: 2.01 (unch)
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million
BusinessWire - Wed Jun 15, 4:00PM CDT
Cytori Therapeutics, Inc. ("Cytori" or the "Company"
(NASDAQ: CYTX) announced today the closing of its rights offering ("Rights Offering" to subscribe for units at a subscription price of $2.55 per unit. CYTX: 2.01 (unch)
Cytori Cell Therapy(TM) Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model
BusinessWire - Fri Jun 10, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large animal model of urethral injury.
CYTX: 2.01 (unch)
Presentation of Twelve Month Pilot Trial Data of Cytori(R) Cell Therapy(TM) for ACL Reconstruction
BusinessWire - Wed Jun 08, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today Dr. Ramon Cugat MD, Ph.D. will present 12-month follow-up results from a 20-patient, single arm, open label pilot study on the use of Cytori Cell Therapy in anterior cruciate ligament (ACL) reconstruction. The presentation is titled 'Biological Augmentation of ACL Reconstruction' and will be made to The Orthobiologic Institute (TOBI) 7th Annual PRP and Regenerative Medicine Symposium in Las Vegas on June 10, 2016.
CYTX: 2.01 (unch)
Cytori Announces Enrollment Completion in U.S. Phase III Scleroderma Trial
BusinessWire - Tue Jun 07, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced completion of enrollment for its U.S. FDA approved Phase III STAR trial. A total of 88 patients were enrolled ahead of schedule, and all procedures were completed successfully without complications.
CYTX: 2.01 (unch)
Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing
BusinessWire - Mon Jun 06, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and adjusted the subscription price for its previously announced rights offering until 5:00 PM Eastern Time on Friday, June 10, 2016. Rights holders will need to exercise their subscription rights prior to that date and time. The adjusted unit pricing is now $2.55 per unit. Furthermore, Cytori invites stockholders to call in for a corporate presentation on Monday, June 6, 2016, at 2:00 PM Eastern Time.
CYTX: 2.01 (unch)
Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
BusinessWire - Tue May 31, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants to purchase shares of common stock to existing stockholders. The rights offering will remain open until 5:00 PM Eastern Time on Thursday, June 9, 2016, unless extended. Rights holders will need to exercise their subscription rights prior to that date and time.
CYTX: 2.01 (unch)
Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial
BusinessWire - Wed May 25, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
CYTX: 2.01 (unch)
Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering
BusinessWire - Tue May 17, 6:15AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering. Stockholders are advised to ensure they own Cytori's stock as of 4:00 PM ET on Tuesday, May 17, 2016 to be considered a stockholder of record on Friday, May 20, 2016. Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below.
CYTX: 2.01 (unch)
European Scleroderma Trial Investigating Cytori Cell Therapy to Be Presented in Japan
BusinessWire - Tue May 17, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use of Cytori Cell Therapy in the treatment of scleroderma-related hand dysfunction will be delivered at the 104th Annual Meeting of the Japan Society of Aesthetic Surgery in Tokyo, Japan.
CYTX: 2.01 (unch)
Cytori Reports First Quarter 2016 Business and Financial Results
BusinessWire - Tue May 10, 3:25PM CDT
Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company"
today announced its first quarter financial results and provided updates on its corporate activity and clinical development. CYTX: 2.01 (unch)
Cytori Granted Broad European Orphan Drug Designation
BusinessWire - Tue May 10, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy(R) formulations when used for the treatment of hand dysfunction and Raynaud's Phenomenon in patients with scleroderma.
CYTX: 2.01 (unch)
Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy
BusinessWire - Fri May 06, 7:39AM CDT
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today the presentation of six and twelve month data from the ATHENA Trials at the annual meeting of The Society for Cardiovascular Angiography and Interventions. The ATHENA trials are two prospective, randomized (2:1, active : placebo), double-blind, controlled, parallel group trials (ATHENA and ATHENA II) each assessing Cytori Cell Therapy(R) [ATHENA: 20 million cells, 28 patients; ATHENA II: 40 million cells, 3 patients]. The objective of the ATHENA program was assessment of safety and feasibility of Cytori Cell Therapy using the Celution(R) System automated on-site manufacturing of the cellular therapeutic and intramyocardial delivery for treatment of chronic ischemic heart disease with left heart failure.
CYTX: 2.01 (unch)
Cytori Reports Preliminary Preclinical Data Supporting Use of Cytori Cell Therapy(TM) for Both the Prevention and Treatment of Hypertrophic Scars
BusinessWire - Thu May 05, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today presented preclinical data at the Annual Meeting of the American Burn Association (ABA) in Las Vegas showing the potential of Cytori's DCCT-10 cell therapy for hypertrophic scarring (HTS), a common consequence of burn injury.
CYTX: 2.01 (unch)
Cytori to Webcast First Quarter Financial Results on May 10
BusinessWire - Fri Apr 29, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Tuesday, May 10, 2016 at 5:30 PM Eastern Time.
CYTX: 2.01 (unch)
Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.01 (unch), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial
BusinessWire - Wed Apr 27, 6:00AM CDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 60th patient (75% of target enrollment). In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 40 patients and recommended that the study continue as planned. The 60 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully without complications.
CYTX: 2.01 (unch)
Cytori Therapeutics (CYTX) Shows Strength: Stock Up 13.2%
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:15AM CDT
Cytori Therapeutics, Inc. (CYTX) shares rose above 13% in the last trading session.
CYTX: 2.01 (unch), ANIK: 52.79 (-0.51)
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016
ACCESSWIRE - Mon Apr 18, 10:17AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SKLN, STEM, CYTX, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
SKLN: 0.14 (unch), CYTX: 2.01 (unch), STEM: 0.39 (-0.01)
